explore -WSS

explore

author：hotspot 2025-09-30 14:34:32 - browse：2

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Medicare details structure of new drug price negotiation program
Next article： Study: AI not yet building 'n

WSS

Bird flu outbreak in cows is latest avian flu curveball

Chamber of Commerce, DOJ clash in court over drug prices

Medicare says breakthrough device reimbursement rule to come by summer

Patients, doctors press FTC to beef up hospital merger scrutiny

Akili changes sales model for its ADHD video game treatment

What happened to the House vote on health price transparency?

focus

explore

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Chamber of Commerce, DOJ clash in court over drug prices

ChatGPT in medicine: STAT answers readers' burning questions

Fed up with FDA, ALS advocates consider a take

ChatGPT in medicine: STAT answers readers' burning questions

White House Covid adviser calls on docs to combat misinformation

State Dept. review finds Biden bears some blame for Afghanistan failures

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Duchenne breakthrough therapy leaves behind pioneering families

How the messy conversation about Dolly changed bioethics

focus

H5N1 bird flu: what we're starting to learn about infection in cows

Chamber of Commerce, DOJ clash in court over drug prices

What nurses really want: sufficient staffing for patient care

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Why the quest to eradicate polio has stumbled

Shionogi licenses Pompe disease therapy from Maze Therapeutics

entertainment

focus

focus

hotspot